* participants who do not develop mild to moderate symptoms within 28 days of test results * participants with rapid clinical deterioration, in the opinion of the investigator * participants experiencing severe symptoms according to covid-19 symptom grading tool * history of being human immunodeficiency virus (hiv) positive; by history only; participants do not need to confirm by testing * participant has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol * participants receiving any contraindicated medication that in the opinion of the investigator cannot be continued while receiving study drug and cannot be held for the duration of the 14-day study treatment period safely * history of unstable cardiac disease in the past 6 months * history of prolonged qt interval, or on other cardiac medications known to prolong the qt interval * use of strong inhibitors and inducers of cyp3a4 is prohibited. lopinavir/ritonavir (l/r) is primarily metabolized by cyp3a4. therefore, concomitant use of strong inhibitors of cyp3a4 (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nelfinavir and saquinavir), and inducers of cyp3a (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. john's wort) are not permitted. the use of other herbals will be reviewed on a case-by-case basis. if they are deemed to be strong modulators of cyp3a4, patients will be excluded if they are unable or unwilling to stop taking them * women who plan to breast feed while on this study are not eligible for participation due to the potential for unnecessary adverse event risks to a child

* participants who do not develop mild to moderate symptoms within 28 days of test results * participants with rapid clinical deterioration, in the opinion of the investigator * participants experiencing severe symptoms according to covid-19 symptom grading tool * history of being human immunodeficiency virus (hiv) positive; by history only; participants do not need to confirm by testing * participant has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol * participants receiving any contraindicated medication that in the opinion of the investigator cannot be continued while receiving study drug and cannot be held for the duration of the 14-day study treatment period safely * history of unstable cardiac disease in the past 6 months * history of prolonged qt interval, or on other cardiac medications known to prolong the qt interval * use of strong inhibitors and inducers of cyp3a4 is prohibited. lopinavir/ritonavir (l/r) is primarily metabolized by cyp3a4. therefore, concomitant use of strong inhibitors of cyp3a4 (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nelfinavir and saquinavir), and inducers of cyp3a (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. john's wort) are not permitted. the use of other herbals will be reviewed on a case-by-case basis. if they are deemed to be strong modulators of cyp3a4, patients will be excluded if they are unable or unwilling to stop taking them * women who plan to breast feed while on this study are not eligible for participation due to the potential for unnecessary adverse event risks to a child

- participants who do not develop mild to moderate symptoms within 28 days of test results - participants with rapid clinical deterioration, in the opinion of the investigator - participants experiencing severe symptoms according to covid-19 symptom grading tool - history of being human immunodeficiency virus (hiv) positive; by history only; participants do not need to confirm by testing - participant has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol - participants receiving any contraindicated medication that in the opinion of the investigator cannot be continued while receiving study drug and cannot be held for the duration of the 14-day study treatment period safely - history of unstable cardiac disease in the past 6 months - history of prolonged qt interval, or on other cardiac medications known to prolong the qt interval - use of strong inhibitors and inducers of cyp3a4 is prohibited. lopinavir/ritonavir (l/r) is primarily metabolized by cyp3a4. therefore, concomitant use of strong inhibitors of cyp3a4 (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nelfinavir and saquinavir), and inducers of cyp3a (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. john's wort) are not permitted. the use of other herbals will be reviewed on a case-by-case basis. if they are deemed to be strong modulators of cyp3a4, patients will be excluded if they are unable or unwilling to stop taking them - women who plan to breast feed while on this study are not eligible for participation due to the potential for unnecessary adverse event risks to a child

- participants who do not develop mild to moderate symptoms within 28 days of test results - participants with rapid clinical deterioration, in the opinion of the investigator - participants experiencing severe symptoms according to covid-19 symptom grading tool - history of being human immunodeficiency virus (hiv) positive; by history only; participants do not need to confirm by testing - participant has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol - participants receiving any contraindicated medication that in the opinion of the investigator cannot be continued while receiving study drug and cannot be held for the duration of the 14-day study treatment period safely - history of unstable cardiac disease in the past 6 months - history of prolonged qt interval, or on other cardiac medications known to prolong the qt interval - use of strong inhibitors and inducers of cyp3a4 is prohibited. lopinavir/ritonavir (l/r) is primarily metabolized by cyp3a4. therefore, concomitant use of strong inhibitors of cyp3a4 (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nelfinavir and saquinavir), and inducers of cyp3a (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. john's wort) are not permitted. the use of other herbals will be reviewed on a case-by-case basis. if they are deemed to be strong modulators of cyp3a4, patients will be excluded if they are unable or unwilling to stop taking them - women who plan to breast feed while on this study are not eligible for participation due to the potential for unnecessary adverse event risks to a child